TORONTO, July 9 /PRNewswire-FirstCall/ - Lorus Therapeutics Inc. (TSX: LOR, AMEX: LRP) ("Lorus" or the "Corporation"), a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, today announced progress made in the Virulizin(R) development program, including the publication of two research studies on the Virulizin(R) mode of action and the issuance of a new patent for Virulizin(R) in Mexico.
"Publication of these two studies in international scientific journals adds significantly to our previous studies on Virulizin(R) anticancer mechanisms and activities," commented Dr. Aiping Young, Lorus' President and CEO. "In addition, allowance of a new patent strengthens the intellectual property position for this product, and protects the potential for expanding the use to other cancer indications in this jurisdiction."
New Virulizin(R) patent issued in Mexico
The patent, titled "Immunomodulating Compositions from Bile for the Treatment of Immune System Disorders", protects methods of treating several cancers using Virulizin(R). This is the second patent issued in Mexico for Virulizin(R), and extends patent protection for Virulizin(R) in this country to 2016. Similar patents for Virulizin(R) have also been issued in a number of other countries worldwide, including Canada, Australia, and the United States.
Virulizin(R) is currently approved for the treatment of malignant melanoma in Mexico. The new patent provides protection for the potential treatment with Virulizin(R) of additional cancers, including ovarian and lung cancers. Virulizin(R) composition, manufacturing process, and use in the treatment of cancers are also protected in Mexico under an earlier patent issued to Lorus in 2003.
Virulizin(R) has demonstrated significant anticancer activity against a
wide range of human cancers in preclinical studies, and has been tested in
|SOURCE Lorus Therapeutics Inc.|
Copyright©2008 PR Newswire.
All rights reserved